May 22, 2013
|
7.0 KB |
|
| |
LEXINGTON, Mass., May 22, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today announced that the Company will be presenting at the Deutsche Bank 38th Annual dbAccess Health Care Conference at 8:40 a.m. ET on May 29, 2013, in Boston.
...
|
May 16, 2013
|
8.6 KB |
|
| |
LEXINGTON, Mass., May 16, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today announced that a clinical abstract reporting Phase I clinical results of CUDC-427, a small molecule antagonist of IAP proteins, has been selected for oral p...
|
May 10, 2013
|
54.6 KB |
|
| |
LEXINGTON, Mass., May 10, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today announced that Erivedge® (vismodegib) was approved for marketing registration by Australia's Therapeutic Goods Administration (TGA) for the treatment o...
|
Apr 30, 2013
|
18.1 KB |
|
| |
LEXINGTON, Mass., April 30, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today reported its financial results for the first quarter ended March 31, 2013.
"This quarter was marked by the continued progress of our proprietary drug ...
|
Apr 26, 2013
|
12.0 KB |
|
| |
- Recommended as Treatment for Advanced Basal Cell Carcinoma -- Curis Eligible for $6 Million Milestone on European Commission Approval -
LEXINGTON, Mass., April 26, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today announced th...
|
Apr 24, 2013
|
7.0 KB |
|
| |
LEXINGTON, Mass., April 24, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today announced that the Company will be presenting at the Needham 12th Annual Healthcare Conference at 8:40 a.m. ET on May 1, 2013, in New York City.
Dan P...
|
Apr 23, 2013
|
6.7 KB |
|
| |
LEXINGTON, Mass., April 23, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its first quarter financial results on Tuesday, April 30, 2013, before the market opens. The Company's management will also h...
|
Mar 29, 2013
|
6.8 KB |
|
| |
LEXINGTON, Mass., March 29, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today announced that the Company will be presenting at the BioCentury Future Leaders in the Biotech Industry Conference at 11:30 a.m. ET on April 5, 2013, in Ne...
|
Mar 11, 2013
|
9.0 KB |
|
| |
LEXINGTON, Mass., March 11, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today announced the appointment of Kenneth Pienta, M.D. to its Board of Directors. Dr. Pienta currently serves as the Donald S. Coffey Professor of Urology, Pro...
|
Mar 11, 2013
|
7.2 KB |
|
| |
LEXINGTON, Mass., March 11, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today announced that the Company will present at the Roth Capital Partners 25th Annual Growth Stock Conference at 11:30 a.m. PT on March 18, 2013, in Dana Point...
|
Feb 25, 2013
|
7.4 KB |
|
| |
LEXINGTON, Mass., Feb. 25, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today announced that the Company will be presenting at the Cowen and Company 33rd Annual Health Care Conference at 4:10 p.m. EST on March 4, 2013, in Boston.
...
|
Feb 20, 2013
|
23.3 KB |
|
| |
LEXINGTON, Mass., Feb. 20, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today reported its financial results for the fourth quarter and year ended December 31, 2012.
"During the last few months, we have taken key steps to strengt...
|
Feb 19, 2013
|
9.9 KB |
|
| |
- Brings Over 20 Years of Experience in Cancer Research, Drug Discovery and Development, Including Nexavar® (sorafenib) and PD-0332991 (palbociclib) -
LEXINGTON, Mass., Feb. 19, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, t...
|
Feb 15, 2013
|
7.4 KB |
|
| |
LEXINGTON, Mass., Feb. 15, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today announced that the Company will be presenting at the following upcoming conferences in New York City:Citi 2013 Global Healthcare Conference — Monday,...
|
Feb 13, 2013
|
7.1 KB |
|
| |
LEXINGTON, Mass., Feb. 13, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its fourth quarter and year end 2012 financial results on Wednesday, February 20, 2013, before the market opens. The Company's...
|
Jan 24, 2013
|
13.5 KB |
|
| |
LEXINGTON, Mass., Jan. 24, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the first patient has been treated in a Phase I clinical study of CUDC-907 in patients with relapsed or refractory lymphoma or...
|
Dec 12, 2012
|
11.3 KB |
|
| |
LEXINGTON, Mass., Dec. 12, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has closed the previously announced $30 million debt transaction with BioPharma Secured Debt Fund II Sub, S.àr.l ("Bio...
|
Dec 6, 2012
|
10.2 KB |
|
| |
LEXINGTON, Mass., Dec. 6, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Patent and Trademark Office has issued a patent covering a genus of compounds that includes Debio 0932, an orally-admi...
|
Dec 6, 2012
|
7.2 KB |
|
| |
LEXINGTON, Mass., Dec. 6, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will be presenting at the Oppenheimer 23rd Annual Healthcare Conference at 2:10 p.m. EST on December 13, 2012, in New York City.
Dan Pas...
|
Nov 28, 2012
|
15.8 KB |
|
| |
- Company to Advance Development of Novel Oncology Therapeutics Including IAP Inhibitor GDC-0917 -- Conference Call Today at 8:30 a.m. EST -
LEXINGTON, Mass., Nov. 28, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, to...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter
